Detecting the MET Exon 14 Skipping Mutations in NSCLC
Willemina R. Geurts-Giele, PhD, discusses 2 approaches used to detect the MET exon 14 skipping mutation in patients with non-small cell lung cancer.
Willemina R. Geurts-Giele, PhD, University Medical Center, Rotterdam, The Netherlands, discusses 2 approaches used to detect theMETexon 14 skipping mutation in patients with non-small cell lung cancer (NSCLC).
Clinicians can use either RNA or DNA, Geurts-Giele says. With RNA, a simple polymerase chain reaction is used because it is the same event, which is very easy. However, the downside is that patients with NSCLC do not have as much material.
DNA analyses are routinely done in pathology departments, while the use of RNA is still evolving in labs. In her analysis, Guerts-Giele used DNA analysis to determine theMETexon 14 skipping mutation because they regularly run the analysis on their patient’s materials.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
